Medicare prescription drug cost, prescriptions and prescribers, 2024
Medicare cost, 2024
$375.7M
-17.6% from 2023
Prescriptions
852K
$440.98 per claim
Patients
186K
102,184 prescribers
Total spending, 2024
$375.9M
$2,025.13 per patient
Medicare prescription drug plans paid $375.7M for Incruse Ellipta in 2024, for 852,075 prescriptions and refills to 185,543 patients (down 17.6% from 2023). The average cost per claim was $440.98.
New York had the highest Medicare cost for Incruse Ellipta in 2024: $44.5M for 102,284 claims, followed by Pennsylvania ($22.3M).
Irina Zolotarevskaya, pulmonary disease in Rego Park, NY, had the highest Medicare cost for Incruse Ellipta in 2024: 1,380 claims costing $471K.
Incruse Ellipta is made by GSK plc (GSK), listed in the Medicare spending data as Glaxosmithkline.
All plans and makers
Where the prescribers practice, 2024
By Medicare drug cost
| Prescriber | Type | Claims | Patients | Cost |
|---|---|---|---|---|
| Irina Zolotarevskaya Rego Park, NY | Pulmonary Disease | 1,380 | 202 | $471K |
| Reuven Moshenyat Brooklyn, NY | Pulmonary Disease | 904 | 194 | $320K |
| Jorge Sanchez-Masiques |
| Year | Prescribers | Claims | Patients | Cost |
|---|---|---|---|---|
| 2022 | 110,749 | 1,051,516 | 214,302 | $498.8M |
| 2023 | 108,156 | 948,954 | 201,499 | $456.2M |
| 2024 | 102,184 | 852,075 | 185,543 | $375.7M |
Amount reimbursed by state Medicaid programs, all states
More drugs: top Medicare drugs by cost and the Prescriptions tab.
Official US government data on Medicare prescription drug plans (Part D) and Medicaid drug use. Cost and spending are before the rebates drug makers pay. Prescribers with fewer than 11 claims of the drug are not published.
| Pulmonary Disease |
| 868 |
| 173 |
| $310K |
| Shamim A Najeebi Springfield, MA | Hospitalist | 451 | 81 | $195K |
| Edward A Dimitry Summit, NJ | Pulmonary Disease | 435 | 87 | $178K |
| Essam R Awad Fall River, MA | Pulmonary Disease | 429 | 86 | $173K |
| Ali Hmidi Middletown, NY | Pulmonary Disease | 340 | 90 | $163K |
| Thomas K Chan New York, NY | Pulmonary Disease | 409 | 59 | $150K |
| Chih M Chen Springfield, MA | Hospitalist | 379 | 63 | $149K |
| Jason B Karp Lake Success, NY | Pulmonary Disease | 216 | 69 | $141K |
| Venkata R Dodda Bloomington, IL | Pulmonary Disease | 236 | 63 | $139K |
| Jahn A Pothier North Dartmouth, MA | Internal Medicine | 357 | 60 | $135K |
| Kenneth K Sha Flushing, NY | Pulmonary Disease | 331 | 67 | $135K |
| Baher N Habeeb Madison, WI | Critical Care (Intensivists) | 286 | 56 | $133K |
| Paul D Weinstein Scarsdale, NY | Pulmonary Disease | 290 | 66 | $132K |
| Marie Cheryle P Lingat Hudson, NY | Pulmonary Disease | 326 | 61 | $131K |
| Hataya K Poonyagariyagorn Beaverton, OR | Pulmonary Disease | 276 | 54 | $128K |
| Robert J Pearlstein Plymouth Meeting, PA | Internal Medicine | 386 | 80 | $127K |
| Sergio Bures Katonah, NY | Pulmonary Disease | 191 | 53 | $126K |
| Aiyub Patel Peoria, IL | Pulmonary Disease | 185 | 56 | $126K |
| Misbahuddin Khaja Bronx, NY | Pulmonary Disease | 306 | 75 | $120K |
| Hung D Nguyen Saratoga Springs, NY | Pulmonary Disease | 213 | 51 | $119K |
| Sidharth Bagga Oroville, CA | Internal Medicine | 305 | 70 | $119K |
| Stanley B Cohen New York, NY | General Practice | 323 | 62 | $118K |
| Francis V Adams New York, NY | Pulmonary Disease | 276 | 46 | $113K |
Spending by manufacturer as listed in the spending data
| Manufacturer | Claims | Spending |
|---|---|---|
| Glaxosmithkline GSK | 852,329 | $375.9M |